News & Press Releases 2021

Bridge to Life, Ltd. announced investigational device exemption approval by the U.S. FDA for its VitaSmart™ Liver Machine Perfusion System and plans to enroll the first patient in its U.S. Bridge to HOPE Liver Clinical Trial by the end of 2021.

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by Perceptive Advisors, a leading life sciences investment firm.

Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life’s current and upcoming solutions to make organ transplantations more successful.

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life’s significant financial commitment to manufacture, trial, and launch Tevosol’s portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform.